Evidence map›Paper›PMID 42656260›Full record

ArticleFrontiers in oncology2026

Two novel e13a3 variants detected in CML patients and their DNA breakpoint analysis.

Dong Liang, Jianmei Chang, Zhifang Xu, Fanggang Ren, Binai Yang, Xiuhua Chen, Hongwei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dong LiangDepartment of Blood Transfusion, Peking University First Hospital Taiyuan Hospital (Taiyuan Central Hospital), Taiyuan, China.
Jianmei ChangThe Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University, Taiyuan, China.
Zhifang XuThe Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University, Taiyuan, China.
Fanggang RenThe Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University, Taiyuan, China.
Binai YangDepartment of Blood Transfusion, Peking University First Hospital Taiyuan Hospital (Taiyuan Central Hospital), Taiyuan, China.
Xiuhua ChenThe Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University, Taiyuan, China.
Hongwei WangThe Key Laboratory of Molecular Diagnosis and Treatment of Hematological Diseases of Shanxi Province, the Second Hospital Of Shanxi Medical University, Taiyuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even in the era of tyrosine kinase inhibitor (TKI) therapy, the prognostic landscape of atypical transcripts in chronic myeloid leukemia (CML) remains poorly defined. In our preliminary work, we identified two atypical transcripts harboring distinct DNA breakpoints that ultimately translate into an identical truncated protein. To investigate the DNA breakpoints of the

Indexed as

aberrant splicingBCR::ABL1chronic myelogenous leukemiaDNA breakpointe13a3

Identifiers

PMID42656260
PMCPMC13506458

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.